[
    "{\"step_by_step_thinking\": \"Based on the information provided in the relevant documents, deucravacitinib has been shown to be effective for psoriasis. Multiple phase 3 trials have demonstrated that deucravacitinib significantly improves psoriasis symptoms, with over 50% of patients achieving a 75% reduction in Psoriasis Area and Severity Index (PASI75) at week 16. The efficacy of deucravacitinib was superior to placebo and apremilast, and the drug was well tolerated with no reports of serious infections or laboratory abnormalities. Therefore, the answer is A. yes.\", \"answer_choice\": \"A\"}"
]